SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-13.21%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$624M
AUM Growth
+$624M
(-3.7%)
Cap. Flow
+$58.5M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
44.27%
Holding
87
New
22
Increased
22
Reduced
22
Closed
15
Top Buys
| 1 |
The Beauty Health Co
SKIN
|
$39.2M |
| 2 |
Organogenesis Holdings
ORGO
|
$13.4M |
| 3 |
AnaptysBio
ANAB
|
$13.1M |
| 4 |
CVS Health
CVS
|
$11.8M |
| 5 |
Tandem Diabetes Care
TNDM
|
$10.9M |
Top Sells
| 1 |
Illumina
ILMN
|
$21.8M |
| 2 |
OraSure Technologies
OSUR
|
$20.7M |
| 3 |
Hologic
HOLX
|
$17.3M |
| 4 |
Smith & Nephew
SNN
|
$12.3M |
| 5 |
Lantheus
LNTH
|
$8.13M |
Sector Composition
| 1 | Healthcare | 89.55% |
| 2 | Consumer Staples | 6.75% |
| 3 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
DexCom
DXCM
$30.9B
| $3.52M | 0.55% |
47,236
+35,627
| +307% | +$59.6K |
|
52
Lyra Therapeutics
LYRA
$11.8M
| $3.35M | 0.52% |
+592,417
| New | +$3.35M |
|
53
FibroGen
FGEN
$48.4M
| $3.19M | 0.5% |
302,226
-762,130
| -72% | -$8.05M |
|
54
IO Biotech
IOBT
$115M
| $3.06M | 0.48% |
655,404
-17,330
| -3% | -$80.9K |
|
55
Alnylam Pharmaceuticals
ALNY
$58.6B
| $2.93M | 0.46% |
+20,100
| New | +$2.93M |
|
56
Xenon Pharmaceuticals
XENE
$2.99B
| $2.28M | 0.36% |
75,000
-114,797
| -60% | -$3.49M |
|
57
C4 Therapeutics
CCCC
$182M
| $2.13M | 0.33% |
282,640
+115,904
| +70% | +$874K |
|
58
Kezar Life Sciences
KZR
$28.5M
| $2.08M | 0.33% |
+252,000
| New | +$2.08M |
|
59
Y-mAbs Therapeutics
YMAB
$390M
| $2.06M | 0.32% |
136,182
-102,800
| -43% | -$1.56M |
|
60
Verastem
VSTM
$585M
| $1.91M | 0.3% |
1,644,500
| – | – |
|
61
PepGen
PEPG
$39M
| $1.74M | 0.27% |
+175,000
| New | +$1.74M |
|
|
KDNY
62
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.54M | 0.24% |
+88,000
| New | +$1.54M |
|
63
CRISPR Therapeutics
CRSP
$4.82B
| $1.34M | 0.21% |
22,000
| – | – |
|
64
Xilio Therapeutics
XLO
$37.5M
| $1.33M | 0.21% |
453,660
-23,835
| -5% | -$69.6K |
|
65
Cullinan Oncology
CGEM
$456M
| $1.22M | 0.19% |
+95,485
| New | +$1.22M |
|
66
Outset Medical
OM
$245M
| $1.03M | 0.16% |
+69,200
| New | +$1.03M |
|
67
NovoCure
NVCR
$1.35B
| $923K | 0.14% |
13,275
-4,000
| -23% | -$278K |
|
68
Immunic
IMUX
$79.4M
| $833K | 0.13% |
240,000
| – | – |
|
69
VistaGen Therapeutics
VTGN
$113M
| $726K | 0.11% |
+825,000
| New | +$726K |
|
|
DALS
70
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $485K | 0.08% |
50,000
-50,000
| -50% | -$485K |
|
|
SIEN
71
DELISTED
Sientra, Inc.
SIEN
| – | – |
-1,641,337
| Closed | -$3.64M |
|
|
OLK
72
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| – | – |
-53,961
| Closed | -$953K |
|
|
ARYD
73
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| – | – |
-300,000
| Closed | -$2.94M |
|
|
TVRD
74
Tvardi Therapeutics, Inc. Common Stock
TVRD
$270M
| – | – |
-159,200
| Closed | -$1.93M |
|
75
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|